IN2012DN02702A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02702A
IN2012DN02702A IN2702DEN2012A IN2012DN02702A IN 2012DN02702 A IN2012DN02702 A IN 2012DN02702A IN 2702DEN2012 A IN2702DEN2012 A IN 2702DEN2012A IN 2012DN02702 A IN2012DN02702 A IN 2012DN02702A
Authority
IN
India
Prior art keywords
compounds
antagonists
lpa
medicaments
diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Ryan Clark
Brian Andrew Stearns
Lucy Zhao
Thomas Jon Seiders
Deborah Volkots
Neannie M Arruda
David Nathan Zalatan
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43128100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN02702(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of IN2012DN02702A publication Critical patent/IN2012DN02702A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2702DEN2012 2009-10-01 2010-09-29 IN2012DN02702A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24787709P 2009-10-01 2009-10-01
PCT/US2010/050786 WO2011041461A2 (fr) 2009-10-01 2010-09-29 Composés polycycliques utiles en tant qu'antagonistes du récepteur de l'acide lysophosphatidique

Publications (1)

Publication Number Publication Date
IN2012DN02702A true IN2012DN02702A (fr) 2015-09-04

Family

ID=43128100

Family Applications (2)

Application Number Title Priority Date Filing Date
IN2702DEN2012 IN2012DN02702A (fr) 2009-10-01 2010-09-29
IN2730DEN2012 IN2012DN02730A (fr) 2009-10-01 2010-09-29

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN2730DEN2012 IN2012DN02730A (fr) 2009-10-01 2010-09-29

Country Status (21)

Country Link
US (3) US8778983B2 (fr)
EP (2) EP2483269A4 (fr)
JP (2) JP2013506680A (fr)
KR (1) KR20120097490A (fr)
CN (2) CN102656168B (fr)
AR (1) AR078495A1 (fr)
AU (1) AU2010300594A1 (fr)
BR (1) BR112012007102A2 (fr)
CA (1) CA2776779A1 (fr)
CL (1) CL2012000812A1 (fr)
EA (1) EA201270467A1 (fr)
GB (1) GB2474748B (fr)
IL (1) IL218962A0 (fr)
IN (2) IN2012DN02702A (fr)
MX (1) MX2012003723A (fr)
PE (1) PE20120997A1 (fr)
PH (1) PH12012500572A1 (fr)
TN (1) TN2012000126A1 (fr)
TW (1) TWI415849B (fr)
UY (1) UY32923A (fr)
WO (2) WO2011041462A2 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068775A2 (fr) 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Antagonistes d'alcyne de récepteurs d'acide lysophosphatidique
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN00754A (fr) 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
CA3007787C (fr) 2010-06-03 2020-03-10 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
US9044479B2 (en) 2010-06-16 2015-06-02 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
WO2012100436A1 (fr) 2011-01-30 2012-08-02 Curegenix Inc. Composé utilisé agissant comme agoniste du récepteur de l'acide lysophospatidique, composition et utilisation
CN103596947A (zh) 2011-04-05 2014-02-19 艾米拉医药股份有限公司 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
MX2013013752A (es) * 2011-05-25 2014-08-01 Intermune Inc Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados.
US8912202B2 (en) 2011-08-08 2014-12-16 Merck Patent Gmbh N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
AU2012296662A1 (en) 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists
GB2493914A (en) * 2011-08-19 2013-02-27 Univ Jw Goethe Frankfurt Main Flurbiprofen and related compounds for the treatment of skin diseases
WO2013070879A1 (fr) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Méthodes de traitement de lésion de la moelle épinière par des antagonistes du récepteur du lpa
EP2783016A1 (fr) 2011-11-22 2014-10-01 Intermune, Inc. Procédés de diagnostic et de traitement de la fibrose pulmonaire idiopathique
US20140329871A1 (en) * 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
EA201492285A1 (ru) * 2012-06-20 2015-04-30 Ф. Хоффманн-Ля Рош Аг Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
CA2879570A1 (fr) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associees a la resistance a des inhibiteurs de la tyrosine kinase de bruton (btk)
ES2667798T3 (es) 2012-12-28 2018-05-14 Ube Industries, Ltd. Compuesto heterocíclico sustituido con halógeno
CN103965664B (zh) * 2013-01-25 2015-07-22 中国石油化工股份有限公司 一种碳黑粒子分散剂及其制备方法和应用
ES2745041T3 (es) 2013-03-13 2020-02-27 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios
JP2016512262A (ja) 2013-03-13 2016-04-25 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 血管炎の処置におけるレボセチリジン及びモンテルカストの使用
AU2014249531B2 (en) 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
CA2938626A1 (fr) 2013-07-26 2015-01-29 John Rothman Compositions permettant d'ameliorer l'avantage therapeutique du bisantrene
GB201314926D0 (en) 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
US9981942B2 (en) * 2013-12-20 2018-05-29 Laboratorios Del Dr. Esteve S.A. Piperidine derivatives having multimodal activity against pain
JP2017078022A (ja) * 2014-02-28 2017-04-27 クミアイ化学工業株式会社 イソキサゾール誘導体及びそれを用いた農園芸用植物病害防除剤
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
HK1245153A1 (zh) * 2014-12-23 2018-08-24 Pharmacyclics Llc Btk抑制剂组合和给药方案
US9729562B2 (en) 2015-03-02 2017-08-08 Harris Corporation Cross-layer correlation in secure cognitive network
HK1252425A1 (zh) 2015-06-05 2019-05-24 Vertex Pharmaceuticals Incorporated 用於治疗脱髓鞘疾病的三唑类药物
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
WO2018106641A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles pour le traitement de maladies démyélinisantes
WO2018106643A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Azoles hétérocycliques pour le traitement de maladies de démyélinisation
WO2018106646A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles pour traiter des maladies démyélinisantes
WO2019041340A1 (fr) * 2017-09-04 2019-03-07 Eli Lilly And Company Composés inhibiteurs du récepteur 1 de l'acide lysophosphatidique (lpar1)
WO2019099294A1 (fr) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Nouveaux composés biaryles substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
CN111344287B (zh) 2017-11-14 2023-12-19 默沙东有限责任公司 作为吲哚胺2，3-双加氧酶(ido)抑制剂的新型取代的联芳基化合物
CN109776351B (zh) * 2017-11-15 2021-11-09 江苏优士化学有限公司 一种重氮乙酸酯连续化合成方法
US11312706B2 (en) 2017-12-19 2022-04-26 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as LPA antagonists
KR102697358B1 (ko) 2017-12-19 2024-08-20 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산
KR102698386B1 (ko) 2017-12-19 2024-08-22 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산
WO2019126103A1 (fr) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Acides pyrazoles azoles cyclohexyliques utilisés en tant qu'antagonistes de lpa
JP7202383B2 (ja) 2017-12-19 2023-01-11 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸
CN112074515B (zh) * 2017-12-19 2025-01-10 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑唑类
EP3728210B1 (fr) 2017-12-19 2026-02-11 Bristol-Myers Squibb Company Acides carbamoyle cyclohexyliques à liaison n isoxazole utilisés en tant qu'antagonistes de lpa
JP7526096B2 (ja) * 2017-12-19 2024-07-31 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン
TW202017918A (zh) 2017-12-19 2020-05-16 美商必治妥美雅史谷比公司 作為lpa拮抗劑之環己基酸三唑吖
US10662172B2 (en) 2017-12-19 2020-05-26 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
KR20200100713A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸
CN108379275B (zh) * 2018-05-29 2020-05-22 中国医学科学院阜外医院 溶血磷脂酸、溶血磷脂酸受体3以及溶血磷脂酸受体3激动剂的应用
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN113366000A (zh) 2018-09-18 2021-09-07 百时美施贵宝公司 作为lpa拮抗剂的氧杂双环酸
SG11202105276TA (en) 2018-12-03 2021-06-29 Univ Texas Oligo-benzamide analogs and their use in cancer treatment
US12466804B2 (en) 2019-06-18 2025-11-11 Bristol-Myers Squibb Company Cyclobutyl carboxylic acids as LPA antagonists
EP3986552B1 (fr) 2019-06-18 2024-09-18 Bristol-Myers Squibb Company Acides carboxyliques isoxazole en tant qu'antagonistes de lpa
EP4058144A1 (fr) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Pyridylsulfonamides de carbamate de triazole utilisées en tant qu'antagonistes du récepteur de lpa et leurs utilisations
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
CA3171979A1 (fr) 2020-03-27 2021-09-30 Josep Bassaganya-Riera Ligands de plxdc2
WO2021236518A1 (fr) 2020-05-19 2021-11-25 IRR, Inc. Lévocétirizine et montélukast utilisés dans le traitement du sepsis et de ses symptômes
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
KR102913125B1 (ko) 2020-06-03 2026-01-20 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
KR102809527B1 (ko) * 2021-01-22 2025-05-21 서울대학교산학협력단 G 단백질 연결 수용체의 억제제를 이용한 상아질 재생 촉진용 조성물 및 제제
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
CA3218917A1 (fr) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Antagonistes du recepteur lpa et leurs utilisations
WO2022241023A1 (fr) 2021-05-13 2022-11-17 Gilead Sciences, Inc. Antagonistes du récepteur lpa et leurs utilisations
KR20240115978A (ko) 2021-12-08 2024-07-26 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
CN114907282B (zh) * 2022-05-24 2023-08-22 华南理工大学 一种合成4-苯基烯基异噁唑衍生物的方法
KR20260019497A (ko) * 2023-06-02 2026-02-10 주식회사 메타이뮨 섬유성 질환 치료용 화합물
CN121568933A (zh) * 2023-07-28 2026-02-24 武汉朗来科技发展有限公司 作为lpar1拮抗剂的化合物、其药物组合物和用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
CA2276034A1 (fr) 1996-12-23 1998-07-02 Mimi Lifen Quan Oxygene ou soufre contanant des hetero-aromatiques utilises comme inhibiteurs du facteur xa
JP3237608B2 (ja) 1997-04-21 2001-12-10 住友製薬株式会社 イソキサゾール誘導体
AU4327600A (en) 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Aryl sulfonyls as factor xa inhibitors
ATE420878T1 (de) * 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
WO2001072723A1 (fr) * 2000-03-28 2001-10-04 Nippon Soda Co.,Ltd. Derived d'oxa(thia)zolidine et medicament anti-inflammatoire
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
EP1340749A4 (fr) 2000-11-17 2007-09-05 Takeda Pharmaceutical Derives d'isoxazole
DE60234318D1 (de) 2001-02-08 2009-12-24 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
ATE406915T1 (de) 2001-07-17 2008-09-15 Ono Pharmaceutical Co Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
AU2002367129A1 (en) 2001-12-25 2003-07-15 Ajinomoto Co., Inc. Organ fibrosis inhibitors
JP2003261545A (ja) 2001-12-28 2003-09-19 Takeda Chem Ind Ltd 神経栄養因子産生・分泌促進剤
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20050101518A1 (en) 2002-01-18 2005-05-12 David Solow-Cordero Methods of treating conditions associated with an EDG-2 receptor
JP4547912B2 (ja) * 2002-03-05 2010-09-22 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
WO2003094965A2 (fr) 2002-05-08 2003-11-20 Neuronova Ab Modulation de cellules souches neurales et de cellules progenitrices neurales
CA2484233A1 (fr) 2002-05-13 2003-11-27 Eli Lilly And Company Composes multicycliques que l'on utilise comme antagonistes de l'hormone de concentration de melanine dans le traitement de l'obesite et du diabete
JP4596314B2 (ja) 2002-05-28 2010-12-08 小野薬品工業株式会社 β−アラニン誘導体およびその用途
WO2004002530A1 (fr) 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. Remede pour maladie chronique
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
CA2506243A1 (fr) 2002-11-19 2004-06-03 Amgen Inc. Genes amplifies impliques dans un cancer
US20050065194A1 (en) 2003-01-16 2005-03-24 Geetha Shankar Methods of treating conditions associated with an Edg-2 receptor
US20040167132A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associted with an Edg-2 receptor
US20040192739A1 (en) 2003-01-16 2004-09-30 David Solow-Cordero Methods of treating conditions associated with an Edg-2 receptor
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
JP2007525449A (ja) 2003-04-11 2007-09-06 ザ ユニバーシティー オブ テネシー リサーチ ファウンデーション リゾホスファチジン酸アナログおよび新生内膜形成の阻害方法
WO2004099164A1 (fr) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Diphenyl isoxazoles, pyrazoles et oxadiazoles substitues, destines au traitement d'une infection par le vhc
EP1638551B1 (fr) 2003-05-19 2011-12-21 Irm Llc Composes immunosuppresseurs et compositions
WO2005012269A1 (fr) 2003-08-05 2005-02-10 Ajinomoto Co., Inc. Nouveau compose azole
US7217704B2 (en) 2003-10-09 2007-05-15 The University Of Tennessee Research Foundation LPA receptor agonists and antagonists and methods of use
US7875745B2 (en) 2003-12-19 2011-01-25 Ono Pharmaceutical Co., Ltd. Compounds having lysophosphatidic acid receptor antagonism and uses thereof
DE10360369A1 (de) 2003-12-22 2005-07-14 Bayer Cropscience Ag Amide
WO2005123671A1 (fr) * 2004-06-22 2005-12-29 Taisho Pharmaceutical Co., Ltd. Dérivé du pyrrole
JP2006096712A (ja) 2004-09-30 2006-04-13 Senju Pharmaceut Co Ltd Ｌｐａ受容体拮抗剤を含有する角膜知覚改善剤
EP1893591A1 (fr) 2005-06-08 2008-03-05 Novartis AG Oxadiazoles polycycliques ou soxazoles i et leur utilisation comme ligands recepteurs de s1p
WO2007007588A1 (fr) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. Compose comportant un groupe cyclique ayant un noyau plan
CA2619101A1 (fr) 2005-08-23 2007-03-01 Irm Llc Composes immunosuppresseurs et compositions associees
CA2643670A1 (fr) 2006-02-27 2007-08-30 Sterix Limited Compose
US20090029949A1 (en) 2006-05-25 2009-01-29 Parrill-Baker Abby L GPCR Ligands Identified by Computational Modeling
JP2009545531A (ja) 2006-07-24 2009-12-24 ユニバーシティ オブ バージニア パテント ファンデーション ホスホン酸ビニルリゾホスファチジン酸受容体拮抗薬
WO2008024979A2 (fr) 2006-08-24 2008-02-28 The Scripps Research Institute Procédés d'utilisation de lysophospholipides de signalisation cellulaire
US20080051372A1 (en) 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
WO2008112201A2 (fr) 2007-03-12 2008-09-18 The General Hospital Corporation Récepteur d'acide lysophosphatidique ciblant une maladie pulmonaire
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2009011850A2 (fr) 2007-07-16 2009-01-22 Abbott Laboratories Nouveaux composés thérapeutiques
CN105418450A (zh) 2008-05-05 2016-03-23 赛诺菲-安万特 酰基氨基取代的稠合环戊烷羧酸衍生物及它们作为药物的用途
JP4933512B2 (ja) 2008-10-09 2012-05-16 住友化学株式会社 導光板
WO2010068775A2 (fr) 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Antagonistes d'alcyne de récepteurs d'acide lysophosphatidique
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN00754A (fr) 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
WO2011041551A1 (fr) * 2009-10-01 2011-04-07 Intermune, Inc. Peptides antiviraux thérapeutiques
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
AU2010340369B2 (en) * 2010-01-06 2014-06-05 Apple Inc. Device, method, and graphical user interface for mapping directions between search results

Also Published As

Publication number Publication date
WO2011041461A2 (fr) 2011-04-07
EP2483269A4 (fr) 2013-05-01
PE20120997A1 (es) 2012-08-01
CN102770415A (zh) 2012-11-07
TW201125862A (en) 2011-08-01
AR078495A1 (es) 2011-11-09
TWI415849B (zh) 2013-11-21
US10000456B2 (en) 2018-06-19
GB2474748B (en) 2011-10-12
MX2012003723A (es) 2012-05-08
GB2474748A (en) 2011-04-27
EP2483251A2 (fr) 2012-08-08
US20110082164A1 (en) 2011-04-07
US8664220B2 (en) 2014-03-04
WO2011041461A3 (fr) 2011-08-25
CL2012000812A1 (es) 2012-09-07
CN102656168A (zh) 2012-09-05
EA201270467A1 (ru) 2012-09-28
JP2013506680A (ja) 2013-02-28
TN2012000126A1 (en) 2013-09-19
WO2011041462A2 (fr) 2011-04-07
IL218962A0 (en) 2012-07-31
GB201016312D0 (en) 2010-11-10
IN2012DN02730A (fr) 2015-09-11
WO2011041462A3 (fr) 2011-08-11
CN102770415B (zh) 2014-09-24
US20140256744A1 (en) 2014-09-11
KR20120097490A (ko) 2012-09-04
US8778983B2 (en) 2014-07-15
JP2013506679A (ja) 2013-02-28
EP2483251B1 (fr) 2016-10-26
US20130072490A1 (en) 2013-03-21
BR112012007102A2 (pt) 2016-04-26
EP2483269A2 (fr) 2012-08-08
PH12012500572A1 (en) 2012-10-22
UY32923A (es) 2010-11-30
EP2483251A4 (fr) 2013-05-01
CA2776779A1 (fr) 2011-04-07
CN102656168B (zh) 2015-04-01
AU2010300594A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
IN2012DN02177A (fr)
IN2012DN02702A (fr)
IN2012DN00754A (fr)
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2010077883A3 (fr) Antagonistes des récepteurs d'acide lysophosphatidique
PH12020550450A1 (en) Certain chemical entities, compositions and methods
PH12015501737B1 (en) Androgen receptor modulators and uses thereof
PH12013500481A1 (en) Estrogen receptor modulators and uses thereof
PH12012502419A1 (en) Estrogen receptor modulators and uses thereof
WO2010068775A3 (fr) Antagonistes d'alcyne de récepteurs d'acide lysophosphatidique
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
IN2012DN02471A (fr)
TN2010000463A1 (en) Compositions and methods for preparing and using same